🔥🐔 BizChicken 🐔🔥

Companies Similar to Verve Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VY-AADC

Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and next-generation platform technologies, with a lead clinical candidate VY-AADC for Parkinson's disease, as well as preclinical programs for various neurological disorders.

Tags: ALS, Alzheimer's disease, Huntington's disease, Parkinson's disease, biotechnology, collaboration, gene therapy, neurological disorders

Symbol: VYGR

Recent Price: $5.59

Industry: Biotechnology

CEO: Dr. Alfred W. Sandrock Jr., M.D., Ph.D.

Sector: Healthcare

Employees: 162

Address: 75 Sidney Street, Cambridge, MA 02139

Phone: 857 259 5340

Leadership

  • Alfred Sandrock, M.D., Ph.D.,
  • Todd Carter, Ph.D., Chief Scientific Officer
  • Jacquelyn Fahey Sandell, Chief Legal Officer
  • Toby Ferguson, M.D., Ph.D., Chief Medical Officer
  • Nathan Jorgensen, Ph.D., MBA, Chief Financial Officer
  • Trista Morrison, Chief Corporate Affairs Officer and Chief of Staff to the CEO
  • Michelle Quinn Smith, Chief Human Resources Officer
  • Robin Swartz, Chief Operating Officer, Principal Financial Officer, and Acting Chief Business Officer
  • Michael Higgins, Chair
  • Grace E. Colón, Ph.D.,
  • James Geraghty,
  • Steven Hyman, M.D,
  • Catherine J. Mackey, Ph.D.,
  • Jude Onyia, Ph.D.,
  • Glenn Pierce, M.D., Ph.D.,
  • George Scangos, Ph.D.,
  • Nancy Vitale,
  • Guangping Gao, Ph.D., Director, University of Massachusetts Medical School (UMMS) Gene Therapy Center & Vector Core; Scientific Director, UMMS-China Program Office; Professor of Molecular Genetics and Microbiology, UMMS.
  • Dinah Sah, Ph.D., Former Chief Scientific Officer of Voyager and former Vice President of Research at Alnylam Pharmaceuticals.
  • Phillip Zamore, Ph.D., Howard Hughes Medical Institute Investigator; Gretchen Stone Cook Chair of Biomedical Sciences, Professor of Biochemistry and Molecular Pharmacology, and Chair of the RNA Therapeutics Institute, University of Massachusetts Medical School.

Last updated: 2024-12-31

Vera Therapeutics, Inc.

Vera Therapeutics, Inc. logo
Market Cap: High
Employees: Low

atacicept

Vera Therapeutics, Inc. is a clinical stage biotechnology company focusing on developing and commercializing treatments for serious immunological diseases, including atacicept for immunoglobulin A nephropathy and MAU868 for BK viremia infections.

Tags: MAU868, atacicept, biotechnology, clinical trial, immunological diseases

Symbol: VERA

Recent Price: $42.06

Industry: Biotechnology

CEO: Dr. Marshall W. Fordyce M.D.

Sector: Healthcare

Employees: 72

Address: 8000 Marina Boulevard, Brisbane, CA 94005

Phone: 650 770 0077

Last updated: 2024-12-31

Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

AV-101

Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for rare cardiopulmonary diseases, with a lead product AV-101 for pulmonary arterial hypertension.

Tags: biopharmaceutical, cardiopulmonary diseases, drug development, pulmonary arterial hypertension

Symbol: AVTE

Recent Price: $2.66

Industry: Biotechnology

CEO: Mr. Timothy P. Noyes M.B.A.

Sector: Healthcare

Employees: 51

Address: 930 Winter Street, Waltham, MA 02116

Phone: 617 443 2400

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

BeiGene, Ltd.

BeiGene, Ltd. logo
Market Cap: Highest
Employees: Highest

BRUKINSA, Tislelizumab, REVLIMID, VIDAZA, XGEVA, BLINCYTO, KYPROLIS, SYLVANT, QARZIBA, Pamiparib, Pobevcy

Bei Gene, Ltd. is a biotechnology company focused on discovering, developing, manufacturing, and commercializing a wide range of medicines globally, specializing in oncology treatments and clinical stage drug candidates.

Tags: Biotechnology, Medicines, Oncology, Pharmaceuticals, Research and Development

Symbol: BGNE

Recent Price: $183.81

Industry: Biotechnology

CEO: Mr. John V. Oyler

Sector: Healthcare

Employees: 10000

Address: 55 Cambridge Parkway, Cambridge, MA 02142

Phone: 781-801-1800

Leadership

  • John V. Oyler, Co-Founder, Chairman and CEO
  • Xiaodong Wang, Ph.D., Co-Founder, Chairman of Scientific Advisory Board
  • Olivier Brandicourt, M.D., Director
  • Margaret Dugan, M.D., Director
  • Donald W. Glazer, Director
  • Michael Goller, Director
  • Anthony Hooper, Director
  • Ranjeev Krishana, Director
  • Michael Nuoqing Yi, Director
  • Alessandro Riva, M.D., Director
  • Corsee Sanders, Ph.D., Director
  • Shalini Sharp, Director
  • Steven Young, Ph.D., Acting Head of Medicinal Chemistry
  • Ron Levy, M.D., Scientific Advisory Board
  • Neal Rosen, M.D., Ph.D., Scientific Advisory Board
  • Charles Sawyers, M.D., Scientific Advisory Board
  • David Schenkein, M.D., Scientific Advisory Board
  • Melika Davis, SVP & Global Head, Clinical Operations
  • Clare Fisher, SVP, Business Development, Licensing, and M&A (ex-China)
  • Tony Guo, Ph.D., SVP, Global Statistics & Data Science
  • Dany Habr, M.D., Head of Medical Affairs, North America & International Markets
  • Graham Hardiman, Global Head of HR
  • Shreya Devendra Jani, SVP, Corporate Affairs
  • Jaspreet Jaggi, M.D., Ph.D., SVP and Head, Clinical Portfolio Strategy
  • Yang Ji, Chief Compliance Officer
  • Mark Lanasa, M.D., Ph.D., SVP, Chief Medical Officer, Solid Tumors
  • Chan Lee, General Counsel
  • Kyu-Sung Lee, Ph.D., SVP, Global Head of Technical Operations and Manufacturing
  • Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer
  • Kyoung Lim, VP of Supply Chain
  • Han Ma, M.D., Ph.D., Chief Safety Officer and SVP, Global Patient Safety
  • Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology
  • Richard O’Keeffe, Head of Global Quality
  • Jurij Petrin, M.D., Head of New Market Development
  • Yan Qi, Ph.D., SVP, Head of Public Affairs
  • Hongyu Qian, SVP, Medical Affairs
  • Jason Radford, SVP, Strategy & Corporate Development
  • Anand Reddi, VP, Global Strategic Initiatives and Corporate Operations, Chief of Staff to the CEO
  • Adam Roach, VP and Head of Asia Pacific
  • Aaron Rosenberg, Chief Financial Officer
  • Michael Schoen, Strategic Advisor and Special Assistant to the CEO
  • Matt Shaulis, General Manager of North America
  • Lai Wang, Ph.D., Global Head of R&D
  • Zhiwei Wang, Ph.D., SVP, Research Head of Chemistry
  • Beth Wensley, SVP, Head of Portfolio and Program Management
  • Kimberly Wolf, SVP, Global Commercial Strategy & Operations
  • Xiaobin Wu, Ph.D., President, Chief Operating Officer
  • Eva Yin, Chief Commercial Officer, Greater China

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Generation Bio Co.

Generation Bio Co. logo
Market Cap: Low
Employees: Low

genetic medicines

Generation Bio Co. is a genetic medicines company developing therapies for rare and prevalent diseases, with a focus on the liver, retina, skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and is headquartered in Cambridge, Massachusetts.

Tags: CNS, genetic medicines, liver, oncology, prevalent diseases, rare diseases, retina, skeletal muscle

Symbol: GBIO

Recent Price: $1.06

Industry: Biotechnology

CEO: Dr. Cameron Geoffrey McDonough M.D.

Sector: Healthcare

Employees: 174

Address: 301 Binney Street, Cambridge, MA 02142

Phone: 617 655 7500

Last updated: 2024-12-31

Keros Therapeutics, Inc.

Keros Therapeutics, Inc. logo
Market Cap: High
Employees: Low

KER-050

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematological and musculoskeletal disorders. Their lead product candidate, KER-050, targets cytopenias, including anemia and thrombocytopenia.

Tags: biopharmaceutical, clinical-stage, cytopenias, hematological disorders, musculoskeletal disorders

Symbol: KROS

Recent Price: $15.64

Industry: Biotechnology

CEO: Dr. Jasbir S. Seehra Ph.D.

Sector: Healthcare

Employees: 149

Address: 99 Hayden Avenue, Lexington, MA 02421

Phone: 617 314 6297

Leadership

  • Jasbir Seehra, Ph.D., Board Member
  • Keith Regnante, M.B.A., Chief Financial Officer
  • Christopher Rovaldi, President, Chief Operating Officer
  • Esther Cho, J.D., Senior Vice President, General Counsel
  • John Oram, M.B.A., Senior Vice President, Program and Portfolio Management
  • Robin Wagner, Senior Vice President, Human Resources
  • Carl L. Gordon, Ph.D., C.F.A., Board Member
  • Jean-Jacques Bienaimé, M.B.A., Lead Independent Director
  • Nima Farzan, M.B.A., Board Member
  • Mary Ann Gray, Ph.D., Board Member
  • Tomer Kariv, J.D., Board Member
  • Julius Knowles, M.B.A., Board Member
  • Ran Nussbaum, Board Member
  • Alpna Seth, Ph.D., Board Member

Last updated: 2024-12-31

Krystal Biotech, Inc.

Krystal Biotech, Inc. logo
Market Cap: High
Employees: Low

beremagene geperpavec (B-VEC)

Krystal Biotech, Inc., a clinical stage biotechnology company, focuses on redosable gene therapy for treating serious rare diseases in the United States, with a pipeline of products at various stages of development.

Tags: biotechnology, clinical stage, gene therapy, rare diseases, redosable gene therapy

Symbol: KRYS

Recent Price: $159.80

Industry: Biotechnology

CEO: Mr. Krish S. Krishnan M.B.A., M.S.

Sector: Healthcare

Employees: 229

Address: 2100 Wharton Street, Pittsburgh, PA 15203

Phone: 412 586 5830

Leadership

  • Krish Krishnan, Board Member
  • Suma Krishnan, Board Member
  • Kathryn Romano, EVP & Chief Accounting Officer
  • Laurent Goux, SVP & General Manager Europe
  • Jennifer McDonough, SVP, Patient Access, Analytics and Operations
  • Christine Wilson, Head of U.S. Sales and Marketing
  • Hiroshi Kasamoto, General Manager Japan
  • David Chien, SVP, Clinical Development
  • Ramesh Arjunji, SVP, Global Value and Access
  • John Thomas, General Counsel & Corporate Secretary
  • Trevor Parry, VP, Research and Scientific Affairs
  • Stéphane Paquette, VP, Business Development
  • Mark A. Petrich, VP, Process Development and Validation
  • Felino Obillo, VP, Global Supply Chain
  • Julian Gangolli, Board Member
  • Catherine Mazzacco, Board Member
  • Kirti Ganorkar, Board Member
  • Dino A. Rossi, Board Member
  • Dan Janney, Board Member
  • Chris Mason, Board Member
  • Rand Sutherland, Board Member

Last updated: 2024-12-31

Lexeo Therapeutics, Inc. Common Stock

Lexeo Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Low

LX2006, LX2020, LX2021, LX2022, LX1001, LX1020, LX1021, LX1004

Lexeo Therapeutics is a clinical-stage genetic medicine company developing innovative gene therapy candidates targeting hereditary and acquired diseases, including cardiomyopathies and neurological conditions.

Tags: APOE4, Batten disease, acquired diseases, cardiomyopathy, gene therapy, genetic medicine, hereditary diseases

Symbol: LXEO

Recent Price: $6.54

Industry: Biotechnology

CEO: Mr. R. Nolan Townsend

Sector: Healthcare

Employees: 69

Address: 345 Park Avenue South, New York, null 10010

Phone: 212-547-9879

Last updated: 2024-12-31

Prime Medicine, Inc.

Prime Medicine, Inc. logo
Market Cap: Medium
Employees: Low

Prime Editors

Prime Medicine, Inc. is a biotechnology company focused on delivering genetic therapies using gene editing technology. Headquartered in Cambridge, Massachusetts, the company was founded in 2019.

Tags: Biotechnology, Gene Editing, Genetic Therapies, Prime Editors

Symbol: PRME

Recent Price: $2.78

Industry: Biotechnology

CEO: Dr. Keith Michael Gottesdiener M.D., Ph.D.

Sector: Healthcare

Employees: 234

Address: 21 Erie Street, Cambridge, MA 02139

Phone: 617-564-0013

Last updated: 2024-12-31

2seventy bio, Inc.

2seventy bio, Inc. logo
Market Cap: Low
Employees: Low

idecabtagene vicleucel

2seventy bio, Inc. is a cell and gene therapy company focusing on cancer treatment research, development, and commercialization, with products including idecabtagene vicleucel and collaborations with Bristol-Myers Squibb.

Tags: biotechnology, cancer treatment, cell therapy, gene therapy, multiple myeloma

Symbol: TSVT

Recent Price: $2.89

Industry: Biotechnology

CEO: Mr. William D. Baird III, M.B.A.

Sector: Healthcare

Employees: 274

Address: 60 Binney Street, Cambridge, MA 02142

Phone: 339 499 9300

Last updated: 2024-12-31

Veracyte, Inc.

Veracyte, Inc. logo
Market Cap: High
Employees: Medium

Afirma Genomic Sequencing Classifier, Xpression Atlas, Decipher Prostate, Prosigna Breast Cancer Assay, Percepta Genomic Sequencing Classifier, Envisia Genomic Classifier, Immunoscore Colon Cancer test

Veracyte, Inc. operates as a diagnostics company worldwide, providing genomic testing solutions for various cancers and diseases, aiming to improve outcomes by avoiding unnecessary surgeries and enhancing treatment decisions.

Tags: Biotechnology, Cancer Diagnosis, Diagnostics, Genomic Testing, Healthcare, Medical Devices

Symbol: VCYT

Recent Price: $40.00

Industry: Biotechnology

CEO: Mr. Marc A. Stapley

Sector: Healthcare

Employees: 815

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 650 243 6300

Last updated: 2024-12-31

Verve Therapeutics, Inc.

Verve Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

VERVE-101

Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.

Tags: VERVE-101, biotechnology, cardiovascular diseases, gene editing, genetic medicines

Symbol: VERV

Recent Price: $5.54

Industry: Biotechnology

CEO: Dr. Sekar Kathiresan M.D.

Sector: Healthcare

Employees: 255

Address: 500 Technology Square, Cambridge, MA 02139

Phone: 617 603 0070

Leadership

  • Andrew Ashe, President, Chief Operating Officer and General Counsel
  • Victoria Bartlett, Vice President, Program and Alliance Management
  • Dan Balian, Associate Director, Supply Chain Management
  • Allen Barrett, Director, Corporate Counsel

Last updated: 2024-12-31

Viveve Medical, Inc.

Viveve Medical, Inc. logo
Market Cap: Lowest
Employees: Lowest

Viveve System

Viveve Medical, Inc., headquartered in Englewood, Colorado, designs and markets medical devices for non-invasive vaginal treatments. Founded in 2005, the company offers the Viveve System which addresses vaginal laxity, sexual function, and stress urinary incontinence.

Tags: medical devices, non-invasive treatment, stress urinary incontinence, vaginal health, vaginal rejuvenation

Symbol: VIVE

Recent Price: $0.00

Industry: Medical - Devices

CEO: Ms. Deborah Ann Jorn M.B.A.

Sector: Healthcare

Employees: 47

Address: Building B, Englewood, CO 80112

Phone: 720 696 8100

Last updated: 2024-12-31

Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc. logo
Market Cap: Lowest
Employees: Low

VP-102, VP-103

Verrica Pharmaceuticals Inc. develops and commercializes treatments for skin diseases in the United States, including products for molluscum contagiosum and warts. The company collaborates with Torii Pharmaceutical Co., Ltd., and Lytix Biopharma AS for further development and commercialization efforts.

Tags: dermatology, molluscum contagiosum, oncology, pharmaceuticals, skin diseases, warts

Symbol: VRCA

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Ted White

Sector: Healthcare

Employees: 100

Address: 44 West Gay Street, West Chester, PA 19380

Phone: 484 453 3300

Last updated: 2024-12-31

Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. logo
Market Cap: High
Employees: Low

VRDN-001, VRDN-002, VRDN-003

Viridian Therapeutics, Inc. is a biotechnology company focused on developing treatments for patients suffering from serious diseases, including thyroid eye disease.

Tags: antibody treatment, biotechnology, clinical trial, therapeutics, thyroid eye disease

Symbol: VRDN

Recent Price: $19.54

Industry: Biotechnology

CEO: Mr. Stephen F. Mahoney J.D., MBA

Sector: Healthcare

Employees: 94

Address: 221 Crescent Street, Waltham, MA 02453

Phone: 617 272 4600

Last updated: 2024-12-31

Verastem, Inc.

Verastem, Inc. logo
Market Cap: Low
Employees: Low

VS-6766

Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing drugs for cancer treatment, with products such as VS-6766 and trials like RAMP 201 and 202 targeting various cancer types.

Tags: MEK, RAF, RAMP 201, RAMP 202, VS-6766, biopharmaceutical, cancer treatment, drug development

Symbol: VSTM

Recent Price: $3.67

Industry: Biotechnology

CEO: Mr. Daniel W. Paterson

Sector: Healthcare

Employees: 73

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 781 292 4200

Last updated: 2024-12-31

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. logo
Market Cap: Low
Employees: Low

EB-101

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.

Tags: EB-101, biopharmaceutical, cell therapy, clinical trials, gene therapy, rare genetic diseases

Symbol: ABEO

Recent Price: $5.61

Industry: Biotechnology

CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.

Sector: Healthcare

Employees: 84

Address: 1330 Avenue of the Americas, New York, NY 10019

Phone: 646 813 4701

Last updated: 2024-12-31

Ventyx Biosciences, Inc.

Ventyx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

VTX958

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.

Tags: VTX002, VTX2735, VTX958, autoimmune disorders, biopharmaceutical, clinical trials, inflammatory diseases, small molecule

Symbol: VTYX

Recent Price: $2.23

Industry: Biotechnology

CEO: Dr. Raju S. Mohan Ph.D.

Sector: Healthcare

Employees: 73

Address: 662 Encinitas Boulevard, Encinitas, CA 92024

Phone: 760 593 4832

Last updated: 2024-12-31